Irma Fernández

Antimicrobial activity of selected Peruvian medicinal plants.

The antimicrobial activity of 36 ethanol extracts from 24 plants, all of them currently used in the Peruvian traditional medicine for the treatment of several infectious and inflammatory disorders, was tested by means of the agar-well diffusion assay against four bacteria (Bacillus subtilis, Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa) and four fungi (Candida albicans, Trichophyton mentagrophytes, Microsporum gypseum and Sporothrix schenckii). Twenty-five (69%) extracts showed some degree of antimicrobial activity against at least one microorganism. The plants with the greatest antimicrobial activity were Cestrum auriculatum L. Heritier (Solanaceae), Iryanthera lancifolia Ducke Suesseng (Myristicaceae), Lepechinia meyenii (Walp.) Epling (Lamiaceae) and Ophryosporus peruvianus (Gmelin) King & H. Rob. (Asteraceae).

Evaluation of the wound-healing activity of selected traditional medicinal plants from Perú

Folk medicine practitioners in Perú employ plant preparations as wound-healing agents on superficial and internal wounds (gastric ulcers). The results of a scientific evaluation of the wound-healing activity of nine plants found in the Amazon jungle near Iquitos and in the Andes mountains is presented. The species studied were: Peperomia galioides, Mentzelia cordifolia, Mutisia acuminata, Himatanthus sucuuba, Spondias mombin, Eleutherine bulbosa, Muehlenbeckia tamnifolia, Anredera diffusa and Jatropha curcas. These plants have also been examined for their toxicological properties, their effect on blood pressure, smooth muscle and capillary permeability. Significant wound-healing activity was detected in Peperomia galioides, Anredera diffusa and Jatropha curcas. Extracts from Peperomia galioides and Anredera diffusa had no effect on cell proliferation and did not exhibit mutagenic activity.

A survey of traditional medicinal plants from the Callejón de Huaylas, Department of Ancash, Perú

The medicinal uses of local flora from the Callejón de Huaylas, Department of Ancash, northeastern Perú, are reported. This geographical area has an old tradition of herbal healing. A total of 33 species have been documented through interactions with village elders, traditional doctors and herbalists. Of the 33 medicinal plant species surveyed in the Callejón de Huaylas, six have not been previously reported, seven have received only minor phytochemical coverage in the literature, and the medicinal uses of seven other plants have not been corroborated with traditional medicinal reports from around the world. The traditional medicinal uses of six medicinal plants have been corroborated with previously published reports but their biological activities have yet to be confirmed in the laboratory. The medicinal uses of four other plants have been corroborated with previously published reports and their biological activities have been confirmed in the laboratory. The purported medicinal use of three plant species could not be confirmed in the laboratory.

Cytotoxic and anti-infective sesquiterpenes present in Plagiochila disticha (Plagiochilaceae) and Ambrosia peruviana (Asteraceae).

A pharmacological screening of the ethanol extract and fractions of two Peruvian medicinal plants, Plagiochila disticha and Ambrosia peruviana, led to the isolation and characterization of three ENT-2,3-secoaromadendrane-type sesquiterpenoids, named plagiochiline A ( 1), I ( 2), and R ( 3), as well as of two pseudoguaianolids, damsin ( 4) and confertin ( 5), which exhibited significant cytotoxic activity against a panel of human tumor cell lines. Compounds 1, 4, and 5 were also investigated for their in vitro antileishmanial, trypanocidal, and antituberculosis activity against Leishmania amazonensis axenic amastigotes and Trypanosoma cruzi trypomastigotes, as well as against MDR and sensitive strains of Mycobacterium tuberculosis, respectively.

Double-blind randomized placebo-controlled study of Bixa orellana in patients with lower urinary tract symptoms associated to benign prostatic hyperplasia.

OBJECTIVE To determine the efficacy of Bixa Orellana (BO) in patients with benign prostatic hyperplasia (BPH) presenting moderate lower urinary tract symptoms (LUTS). MATERIALS AND METHODS It is a prospective double-blind randomized placebo-controlled study. One thousand four hundred and seventy eight patients presenting moderate LUTS associated to BPH were interviewed, from whom we selected 136 to fulfill the criteria of inclusion and exclusion. Assignation was performed at random in blocks of four to receive B0 at a dose of 250 mg 3 times a day or placebo (Pbo) for 12 months, 68 patients were assigned to each group. From the patients in the study we obtained data of demographic, epidemiologic, symptom score, uroflowmetry and post void residual urine variables. RESULTS Basically both groups were compared clinically, demographically and biochemically. Throughout the study variations of symptom score, mean delta symptom score during each visit and the final average delta were similar for both groups (BO - 0.79 +/- 1.87 and Pbo - 1.07 +/- 1.49) (p = 0.33). Similarly variations of Qmax mean, Qmax average delta and final average delta were similar (BO 0.44 +/- 1.07 and Pbo 0.47 +/- 1.32) (p = 0.88). Variations of post void residual urine mean, post void residual urine average delta in each visit and the final average delta were similar for both groups (BO 4.24 +/- 11.69 and Pbo 9.01 +/- 18.66) (p = 0.07). No differences were found in the answers of clinically significant improvement assessed with relative risk and risk differences, even though the proportion of adverse effects was similar for both groups. CONCLUSION Patients with BPH that present moderate LUTS did not show any benefit receiving BO when compared to placebo.